ArticleScientific reports2018
Salinomycin-loaded Nanofibers for Glioblastoma Therapy.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 50 citations in OpenAlex.
- Electrospun Nanofiber Films Containing Hesperidin and Ofloxacin for the Inhibition of Inflammation and Psoriasis: A PotentialCurrent drug delivery · 2025Article
- Recent Advancements in the Diagnosis and Management of Cancer Using Biomaterials-fabricated Nanofibers: A Review.Current medicinal chemistry · 2025Review
- The Golgi Apparatus as an Anticancer Therapeutic Target.Biology · 2023Review
- Electrospun Drug-Loaded and Gene-Loaded Nanofibres: The Holy Grail of Glioblastoma Therapy?Pharmaceutics · 2023Review
- Fabrication and Modelling of a Reservoir-Based Drug Delivery System for Customizable Release.Pharmaceutics · 2022Article
- Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy.Pharmaceutics · 2021Review
- Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy.Pharmaceutics · 2021Review
- Review
- A Smart Hyperthermia Nanofiber-Platform-Enabled Sustained Release of Doxorubicin and 17AAG for Synergistic Cancer Therapy.International journal of molecular sciences · 2021Article
- Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.Scientific reports · 2020Article
- Salinomycin-Loaded Iron Oxide Nanoparticles for Glioblastoma Therapy.Nanomaterials (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Salinomycin is an antibiotic that has recently been introduced as a novel and effective anti-cancer drug. In this study, PLGA nanofibers (NFs) containing salinomycin (Sali) were fabricated by electrospinning for the first time. The biodegradable PLGA NFs had stability for approximately 30 days and exhibited a sustained release of the drug for at least a 2-week period. Cytotoxicity of the NFs + Sali was evaluated on human glioblastoma U-251 cells and more than 50% of the treated cells showed apoptosis in 48 h. Moreover, NFs + Sali was effective to induce intracellular reactive oxygen species (ROS) leading to cell apoptosis. Gene expression studies also revealed the capability of the NFs + Sali to upregulate tumor suppressor Rbl1 and Rbl2 as well as Caspase 3 while decreasing Wnt signaling pathway. In general, the results indicated anti-tumor activity of the Sali-loaded NFs suggesting their potential applications as implantable drug delivery systems in the brain upon surgical resection of the tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.